Lung cancer begins when cells in a lung become abnormal and begin growing out of control. When the abnormal cancer cells grow, they can form into a tumor and even spread to other areas of the body (metastasize). A lung cancer specialist will guide you through the next steps.
Review this section's important information about lung cancer diagnosis, staging, and treatment options, as well as lung cancer patient and survivor resources as you prepare for an appointment with your oncologist. After reviewing these sections, ask your cancer care team any additional questions that you may have about your individual situation.
If your doctor suspects you may have lung cancer, they will order tests to look for cancerous cells and make a lung cancer diagnosis. Your doctor might recommend various tests, including a chest x-ray, biopsy, sputum cytology or imaging tests to diagnose either Non-Small Cell or Small Cell Lung Cancer.
A risk factor is anything that affects a person’s chance of developing a disease, such as cancer. Risk factors differ from cancer to cancer. Some, like smoking, can be changed, others, such as age or genetics, cannot.
There are two types of lung cancer, Small Cell Lung Cancer (SCLC) and Non-Small Cell Lung Cancer (NSCLC), named based on the type of cells found in the cancer and how the cells appear viewed under a microscope.
Cancer staging is the process of gathering information to determine the location and extent of the lung cancer and if it has spread to other parts of the body.
Your type and stage of your lung cancer, as well as various other factors, will dictate your treatment plan. The lung cancer doctors at NYOH work together with you to develop your treatment plan. Your treatment options may include surgery, chemotherapy, radiation therapy, immunotherapy, laser therapy, endoscopic stent placement, or targeted therapy.
From support groups to chemotherapy classes, hereditary risk assessment to financial support through our NYOH Community Cancer Foundation, the cancer specialists at New York Oncology Hematology are here for you every step of the way. We encourage you to learn more and take advantage of our supportive care services.
Lung cancer care is becoming increasingly personalized with tailored treatments targeting the unique cellular characteristics of tumors. To support this, NYOH is participating in the MYLUNG Study, an observational/interventional research trial to deepen our understanding of the disease and improve care for non-small lung cancer (NSCLC) patients. Participation will not impact your prescribed treatment plan.
MYLUNG brings together diverse organizations across the US Oncology network to observe up to 12,000 NSCLC patients over a five-year period. You may be eligible to take part in this study if you have been diagnosed with non-squamous, non-small cell lung cancer.
If you or your loved one is ready to meet with a lung cancer specialist, our team is here to help. Start by requesting an appointment at a location that's convenient for you.
New York Oncology Hematology cancer researchers, partnered with the US Oncology Network, lead the way in finding new cancer treatment options through clinical trials at all NYOH locations.
We are always looking for the latest cancer treatment options for our patients and are also involved with many other types of breakthrough lung cancer research studies. Click for a full list of our available lung cancer research studies.
©2024 New York Oncology Hematology. All rights reserved.